Biosimilars Archives

News and Trends 20 Oct 2022

Alvotech and JAMP Pharma add two biosimilar candidates for Canadian market

Alvotech and the JAMP Pharma Group have expanded their exclusive partnership to commercialize biosimilars developed and manufactured by Alvotech. The…

October 20, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 4 Oct 2022

FDA gives $1.3M grant to Biologics & Biosimilars Collective Intelligence Consortium

The Biologics & Biosimilars Collective Intelligence Consortium (BBCIC) has received a major grant from the Food & Drug Administration (FDA)…

October 4, 2022 - 2 minutesmins - By Jim Cornall

More News! 17 Oct 2018

The EU Patent of the Best Selling Drug Has Expired, What Does it Mean for Biotech?

AbbVie’s Humira, a treatment for inflammatory disease and the world’s best-selling drug, is no longer patent-protected in the EU. Competitors…

October 17, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 18 Sep 2017

German Humira Biosimilar for Inflammatory Diseases Cleared for EMA Approval

Cyltezo, an adalimumab biosimilar drug by Boehringer Ingelheim, has received the backing to be marketed in Europe. The EMA's Committee…

September 18, 2017 - 1 minutemin - By Alex Dale

samsung bioepis imraldi humira adalimumab biosimilar tnf a

News and Trends 28 Aug 2017

Samsung Bioepis Gets European Approval for Biosimilar of Best-Selling Antibody

Samsung Bioepis has announced the European Commission approved Imraldi, a biosimilar of AbbVie's Humira (adalimumab), which has topped revenue charts…

August 28, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

biosimilars market novartis sandoz roche boehringer ingelheim

News and Trends 16 Aug 2017

Biosimilars Struggle to Substitute Brand-Name Drugs

Despite bringing a significant price reduction, biosimilars might lag in taking over the market of the drugs they copy because…

August 16, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 23 Feb 2017

Biosimilars set to take on Oncology after a new Market Authorization

The European Commission has approved Truxima, the world's first biosimilar monoclonal antibody (mAb) with an oncology indication. Based in South…

February 23, 2017 - 3 minutesmins - By Melanie De Almeida

More News! 8 Feb 2017

The FDA lays down Laws of Interchangeability: New Era for Biosimilars?

The new guidelines from the FDA on interchangeability may bring the US biosimilar market up to speed and a new…

February 8, 2017 - 4 minutesmins - By External Contributor

News and Trends 6 Dec 2016

Sanofi Jumps into the Biosimilars Market aiming for Asia

Sanofi is joining the biosimilars trend to challenge Roche's best-selling biological with a partnership that aims to take over the…

December 6, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 17 Nov 2016

Boehringer’s Biosimilar could take a Chunk out of the Cancer Market

Boehringer Ingelheim is getting ready to launch a biosimilar for Roche's cancer blockbuster Avastin as soon as the patent expires.…

November 17, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

card reading fate psychic Miriam Doerr Martin Frommherz fi

News and Trends 17 Nov 2016

What’s in the Cards for a Biosimilar after it Launches

As legal frameworks and regulatory pathways for biosimilars are in evolving all around the world, how will they affect the…

November 17, 2016 - 5 minutesmins - By External Contributor

Sanofi regeneron rheumatoid arthritis salurimab

News and Trends 31 Oct 2016

UPDATE: FDA rejects Sanofi’s promising Rheumatoid Arthritis Drug

Sanofi and Regeneron (NY, US) have ruled their phase III clinical trial immunotherapy Sarilumab a huge success. Now awaiting US…

October 31, 2016 - 3 minutesmins - By Dani Bancroft

News and Trends 27 Oct 2016

Boehringer enters the Biosimilar War against Blockbuster Humira

Boehringer Ingelheim just announced positive Phase III results for its Humira biosimilar. The company is joining many others in the…

October 27, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

cells pipetting well plate cells Andrii Slonchak fi

News and Trends 26 Oct 2016

Biosimilars are all the rage, but how do they compare to Generics?

Biosimilars could be the future of the pharmaceutical industry, as the market could grow 10-fold in the next 5 years.…

October 26, 2016 - 5 minutesmins - By External Contributor

biologics 2015 blockbusters best selling drugs

News and Trends 30 Aug 2016

Top 10 Best-selling Biologicals of 2015

Biological drugs have revolutionised disease treatment and their developers have made a killing along the way. We take a look at…

August 30, 2016 - 6 minutesmins - By Denise Neves Gameiro

cinfa amgen biosimilar biotech neutropenia chemotherapy

News and Trends 5 Jul 2016

Spanish Biotech gets New Milestone in Biosimilar Race with Amgen

The Spanish Cinfa Biotech's race to compete with Amgen's blockbuster for Chemotherapy-induced Neutropenia continues: the Neulasta biosimilar passes Phase I trials. Neulasta…

July 5, 2016 - 2 minutesmins - By Dani Bancroft

samsung bioepis biotech rheumatoid arthritis biosimilar flixabi sb4

News and Trends 5 Apr 2016

Samsung’s Rheumatoid Biosimilar could now make it to the EU Market

Samsung Bioepis (South Korea) has gotten an approval recommendation from the EMA for one of its 13 in-development biosimilars: Flixabi,…

April 5, 2016 - 3 minutesmins - By Denise Neves Gameiro

horizon centarui axxinity venture therapeutics alphamers cancer1

News and Trends 4 Mar 2016

The Best Selling Biologic of All Time now chased by New Phase III Biosimilar

Merck (Germany) has initiated a phase III trial for a biosimilar of AbbVie's Humira, to treat Chronic plaque psoriasis. This is…

March 4, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 26 Jan 2016

2011-2015: What a Fantastic 5 Years for European Biotech

The crisis of 2008 hit the Biotech sector hard, and it wasn't clear how the Biotech industry would get back…

January 26, 2016 - 5 minutesmins - By Philip Hemme

macular degeneration xbrane helvetic xlucane biosimilar lucentis blindness iran

News and Trends 18 Jan 2016

Where there be Patent-Free Markets: Swiss-Swedish Biosimilar for Blindess Reaches Iran

Helvetic BioPharma (Switzerland) estimates that 70,000 people suffer from age-related macular degeneration in Iran, the leading cause of blindness. This…

January 18, 2016 - 2 minutesmins - By Dani Bancroft

Report: new Frontiers in Vaccinology

Listen to our podcast

View all sectors A-Z

The Biotech Perspective 2023

View all companies A-Z

Find new scientific partnerships. Create a free IN-PART account

View all countries A-Z

Report: The European Biotech Startup Ecosystem

Subcribe to our newsletter

Learn more about Inova, the leading platform for biopharma partnering